The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx trial is a phase III randomized, prospective, noninferiority trail that enrolled over 10,000 women with hormone receptor-positive, HER2-negative, early stage breast cancer. Women with a moderate recurrence score (as defined by the Oncotype DX test) of 11 to 25, received endocrine therapy alone or chemotherapy plus endocrine therapy.
Results presented at the annual meeting showed the trail met its primary endpoint of disease-free survival (DFS). Researchers showed 9-year survival rates were similar in both treatment arms for DFS (83.3% vs 84.3%), distant recurrence (94.5% vs 95.0%) and overall survival (OS) (93.9% vs 93.8%). The noninferiority of hormone monotherapy alone was established.